{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-232533","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2026-05-20T20:04:03+00:00","discovered_at":"2026-05-20T20:05:02.875447+00:00","generated_at":"2026-05-20T21:47:39.460056+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer","bullets":["New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.","Expansion effective May 19, 2026, under CMS Molecular Diagnostics Program.","NeXT Personal is an ultrasensitive liquid biopsy test; this indication broadens addressable patient population."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-232533","json":"https://secwatch.observer/filing/0001193125-26-232533.json","markdown":"https://secwatch.observer/filing/0001193125-26-232533.md","text":"https://secwatch.observer/filing/0001193125-26-232533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/0001193125-26-232533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526232533/psnl-20260519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T21:47:39.460056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}